Ortho-Clinical Diagnostics recall
This article was originally published in The Gray Sheet
Executive Summary
J&J subsidiary voluntarily recalls four lots of its Vitros immunodiagnostic troponin I reagent pack after receiving complaints of random false-positive results. Malfunction of the cardiac marker used worldwide to aid diagnosis of myocardial infarction is attributed to a component's interaction with patient plasma samples. Replacements for the affected lots - 2510 and 2530 in the U.S. and 1110 and 1130 worldwide - have been supplied to labs. No injuries have been reported, according to the firm...
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.